# QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension

Study · id `cardio:ct-nct06716970` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06716970](<https://clinicaltrials.gov/study/NCT06716970>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06716970

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 810 participants.

## Technical summary

Registry record NCT06716970. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-30 (anticipated); primary completion 2026-04-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 810 participants (planned count; ClinicalTrials.gov record NCT06716970, source copy `cardio:ctgov-nct06716970-2024-12-06`, retrieved 2026-10-26)
- Planned start: 2024-12-30 (anticipated) (ClinicalTrials.gov record NCT06716970, source copy `cardio:ctgov-nct06716970-2024-12-06`, retrieved 2026-10-26)
- Primary completion: 2026-04-30 (anticipated) (ClinicalTrials.gov record NCT06716970, source copy `cardio:ctgov-nct06716970-2024-12-06`, retrieved 2026-10-26)
- Completion: 2027-02-28 (anticipated) (ClinicalTrials.gov record NCT06716970, source copy `cardio:ctgov-nct06716970-2024-12-06`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06716970, source copy `cardio:ctgov-nct06716970-2024-12-06`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06716970-2024-12-06`, retrieved 2026-10-26)

## The registry's words

- Brief title: QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): QR12000 75mg
- Intervention (Drug): QR12000 75mg placebo
- Intervention (Drug): QR12000 150mg
- Intervention (Drug): QR12000 150mg placebo
- Intervention (Drug): Sacubitril/valsartan 200mg
- Intervention (Drug): Sacubitril/valsartan 200mg placebo
- Lead sponsor: Wuhan Createrna Science and Technology Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 8761ca7f780b71779c03dc44eaff222e15604531db80edc2e599f4703c15942c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
